SNGX SOLIGENIX, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 812796 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY-85.8%
TTM net income YoY-34.6%
TTM EPS YoY60.7%
Revenue 3-yr CAGR-47.5%
Net income 3-yr CAGR—
Margins
Gross margin0.0%
Operating margin-7,907.7%
Net margin-6,925.1%
FCF margin—
EBITDA margin—
Returns
ROE-249.0%
ROA-88.1%
ROIC (approx.)—
Asset turnover0.01x
Leverage & solvency
Liabilities / assets54.1%
Debt / equity0.00x
Current ratio1.82x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.02x
Accruals ratio1.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | $0 |
| Cost of revenue | — | — | — | — | — | — | — | $0 |
| Gross profit | — | — | — | — | — | — | — | $0 |
| R&D expense | $357,012 | $974,091 | $1.78M | $2.28M | $1.58M | $1.68M | $1.94M | $2.66M |
| SG&A expense | $1.02M | $1.13M | $1.10M | $1.19M | $996,604 | $1.09M | $1.08M | $1.05M |
| Operating income | -$1.38M | -$2.10M | -$2.88M | -$3.47M | -$2.58M | -$2.76M | -$3.03M | -$3.71M |
| Pretax income | -$1.12M | -$1.99M | -$2.82M | -$3.40M | -$2.53M | -$2.70M | -$2.95M | -$3.40M |
| Net income | -$1.12M | -$1.99M | -$2.82M | -$2.90M | -$2.53M | -$2.70M | -$2.95M | -$2.99M |
| EPS (basic) | -0.05 | -0.12 | -0.28 | — | -0.58 | -0.82 | -0.97 | — |
| EPS (diluted) | -0.05 | -0.12 | -0.28 | — | -0.58 | -0.82 | -0.97 | — |
| Weighted avg. shares (diluted) | 22.15M | 15.95M | 10.16M | — | 4.33M | 3.28M | 3.05M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $9.02M | $9.81M | $6.03M | $7.94M | $10.53M | $5.10M | $7.30M | $7.82M |
| Current assets | $9.17M | $10.17M | $6.57M | $8.85M | $10.88M | $5.32M | $7.64M | $8.83M |
| PP&E, net | $5,480 | $6,577 | $7,675 | $8,772 | $7,812 | $8,114 | $5,505 | $6,113 |
| Total assets | $9.46M | $10.50M | $6.92M | $9.24M | $9.24M | $5.76M | $7.75M | $8.97M |
| Current liabilities | $3.06M | $3.67M | $3.62M | $3.70M | $3.42M | $3.63M | — | $4.85M |
| Long-term debt | — | — | — | — | — | — | — | $0 |
| Total debt | — | — | — | — | — | — | — | $0 |
| Total liabilities | $3.21M | $3.85M | $3.83M | $3.94M | $3.70M | $3.93M | $3.85M | $4.85M |
| Shareholders' equity | $6.26M | $6.65M | $3.09M | $5.29M | $7.60M | $1.83M | $3.90M | $4.12M |
| Net debt | — | — | — | — | — | — | — | -$7.82M |
| Shares outstanding | 23.37M | 21.64M | 10.52M | 10.09M | 9.86M | 3.50M | 3.18M | 2.51M |
| Cash flow statement | ||||||||
| Operating cash flow | -$1.42M | -$1.71M | -$2.36M | -$2.75M | -$2.93M | -$2.74M | -$1.85M | -$2.23M |
| Capital expenditure | — | — | — | $1,962 | $608 | — | — | — |
| Free cash flow | — | — | — | -$2.75M | -$2.93M | — | — | — |
| Investing cash flow | — | — | — | -$1,962 | -$608 | — | — | — |
| Financing cash flow | $636,378 | $5.49M | $451,000 | $157,884 | $8.36M | $545,635 | $1.32M | $242,878 |
| Stock-based compensation | $86,634 | $115,972 | $121,208 | $320,125 | $104,346 | $99,513 | $63,599 | $155,547 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.